Changes in Hong Kong stocks | Jietai Technology-P (07666) rose nearly 7% in early trading The core competitiveness of Biological AI is real experimental data

The Zhitong Finance App learned that Jetai Technology-P (07666) rose nearly 7% in early trading. As of press release, it rose 5.45% to HK$17.8, with a turnover of HK$69.1574 million.

According to news, the 29th Beijing-Taiwan Science and Technology Forum was held in the Beijing Economic and Technological Development Zone on September 19. Lai Caida, co-founder, chairman and CEO of Jietai Technology, was invited to give a keynote speech on “The Era of Programmable Biology: The New Frontier of AI”. Compared to “how big is the model”, Dr. Lai Caida emphasized another thing: biomedical AI ultimately fights for whether it can continue to obtain high-quality experimental data and transform this data into model capabilities.

According to reports, Lai Caida used a “three-layer cake” to describe the technical architecture of AI pharmaceuticals. The bottom layer is also the thickest first layer. It is a data platform for dry experiments and wet experiments. Generic large models can be obtained from the Internet, but much of the data actually needed for drug delivery, protein, nucleic acid, and cell research comes from laboratories: what kind of tissue does an LNP enter, how different lipid structures affect expression, and how activity changes after changes in protein sequence must be obtained through experiments. The second layer is a perpendicular model generated from this data. The third layer is the big language model and agent.

Since the launch of NanoForge, the world's first AI nano-delivery platform, the new “dry test+wet experiment+smart body” R&D paradigm has fully covered the complete chain of AI protein generation, in vivo delivery technology and next-generation immunotherapy development, forming a closed loop of continuous learning and nano-delivery data barriers. It continues to break through extrachepatic delivery, providing underlying support for the exploration of accurate AI delivery and cellular programming.